All In Biotech

Drug Trial Radar · NCT07446049

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Jan 9, 2028

Study completion Apr 8, 2028

Sponsor

Lead sponsor
Convalife (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression

Conditions

  • Locally Advanced or Metastatic Solid Tumors
  • PTEN Loss or Low Expression

Interventions

  • CVL237 tabletsDrug

    CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary study endpointsTime frame: Up to day 28
  2. Primary Outcome MeasureTime frame: up to day 28
  3. Primary Outcome MeasureTime frame: up to day 28
  4. Primary Study EndpointsTime frame: Up to day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.